We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

Similar documents
End Stage Liver Disease Regional Audit Casenote Survey

Syringe driver in Palliative Care

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

This survey aims to look at individual practice and can be completed by any healthcare professional.

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

SYRINGE DRIVER MEDICATIONS

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Algorithms for Symptom Management. In End of Life Care

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

End of life prescribing guidance

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

What else is new (other symptoms) DR ANDREW DAVIES

Clatterbridge Centre for Oncology

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Controlling nausea and vomiting: anti-emetic therapy advice

Using syringe pumps in palliative care

Part 2: Pain and Symptom Management Nausea and Vomiting

Implementing the recommendation on medication management and symptom control

Guidelines for the Use of Anti-Emetics with Chemotherapy

Isle of Wight Syringe Driver Compatibility Guidelines

BACKGROUND Measuring renal function :

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Syringe Drivers. Back to top

Nausea and Vomiting in Palliative Care

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Conservative Management of Uraemia

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Renal Palliative Care Last Days of Life

A RANDOMISED, OPEN LABEL STUDY OF GUIDELINE DRIVEN TARGETED ANTIEMETIC THERAPY VERSUS SINGLE AGENT ANTIEMETIC THERAPY

Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy

Nausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA

A Study on Evaluation of Anti-Emetics in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients in A Tertiary Care Hospital

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

Supportive Care. End of Life Phase

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network

Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety.

The last days of life in hospital and at home

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Care of the Dying Management in Severe Renal Failure

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Palliative Care Impact Survey

ABC of palliative care: Anorexia, cachexia, and nutrition

Care of the Dying Management in Severe Renal Failure

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

Controlling sickness after chemotherapy

Palliative Care Formulary

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

Palliative Care. Pocketbook 4

Eastern Health and Social Services Board Palliative Care

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Inpatient Palliative Medicine Update

Chemotherapy Induced Nausea and Vomiting

Nausea and Vomiting. Principles and Practice in End of Life Care November 2018

Palliative care for heart failure patients. Susan Addie

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Care in the Last Days of Life

Antiemetics in chemotherapy

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Symptom Management Guidelines for End of Life Care

Gastrointestinal obstruction Dr Iain Lawrie

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

Care of dying adults in the last days of life. Improving care at the very end of life.

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults

CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC

Lothian Palliative Care Guidelines POCKET EDITION 2004

Gastrointestinal obstruction in palliative care: a review

Nausea and Vomiting During Cancer Treatment

Health Learning Partnership End of Life Care 29 th June 2016

HOMES AND SENIORS SERVICES. APPROVAL DATE: February 2011 REVISION DATE: July 2018

Drug: Aprepitant (Emend ) Date of Review: 4/01/10

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director

What s New 2003? What new treatments? What have you discontinued? More information please!

Approach to Nausea & Vomi2ng

Common Palliative Symptoms SEVERN HOSPICE CLINICAL NURSE SPECIALISTS

post-operative, nausea, vomiting, antiemetics

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017

Constipation and bowel obstruction

Grace Ma and Andrea Weiss FMF 2018

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Transcription:

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients. The closing date for responses is 19th December The results of the audit and the prosed new standards and guidelines will be presented at the regional audit meeting on the 15th January 2015 at Marie Curie Hospice, Liverpool. Guideline Development Group for the Management of Nausea and Vomiting in Palliative Care

* 1. Information about you: About you What is your role? Where do you work? Which setting do you work in?

2. What would be your first line choice of antiemetic for nausea and vomiting due to the following aetiologies? Biochemical Drug induced Psychological Constipation (excluding bowel obstruction) Gastroparesis Antiemetic 3. What would your normal practice be in relation to a patient with nausea and vomiting? (Please select all that apply) Provide advice only History Examination Arrange further investigations eg bloods None of the above Don t know 4. Following your initial review of a patient with nausea and/or vomiting when do you reassess the patient? Within 24 hours 48 hours 72 hours Greater than 72 hours If you don't reassess the patient - why not?

5. In which situations would you consider the use of a syringe driver to deliver antiemetics? (Please select all that apply) Symptoms uncontrolled at the time of assessment? If symptoms remain uncontrolled after 24hrs? Loss of appetite without alteration in eating habits Severe nausea and/or vomiting Suspected or known poor absorption Oral intake decreased without significant weight loss, dehydration or malnutrition. IV fluids indicated <24 hrs Inadequate oral caloric or fluid intake; IV fluids, tube feedings, or TPN indicated > 24 hrs 1 vomiting episode in 24 hours 2-5 vomiting episodes in 24 hours > 6 vomiting episodes in 24 hours 6. If nausea and/or vomiting persists do you consider adding a second antiemetic? Yes No 7. What would influence your choice of second antiemetic?

8. When prescribing/suggesting antiemetics do you suggest/prescribe the following... Regular antiemetic only PRN antiemetic only Both regular and PRN antiemetic? Suggest 2nd PRN antiemetic? Prescribing basis If no to both regular&prn - why not? 9. Do you experience difficulties in obtaining antiemetics for any of the following reasons? (Please select all that apply) Cost issues Availability of prescriber Obtaining supply of antiemetics from pharmacies out of hours Other

10. Is it your practice to suggest or prescribe the following medication for the alleviation of nausea and vomiting? (Please select all that apply) Aprepitant Cyclizine Dexamethasone Domperidone Granisetron Haloperidol Hyoscine Butylbromide Hyoscine Hydrobromide Levemepromazine Lorazepam Metoclopramide Octreotide Olanzapine Ondansetron Prochlorperazine Other

11. For the antiemetics listed below please select the maximum doses you suggest and/or prescribe in a 24 hour period and the minimum and maximum stat doses suggested on a PRN basis Maximum dose in 24 hour period Minimum PRN stat dose Maximum PRN stat dose Aprepitant Cyclizine Dexamethasone Domperidone Granisetron Haloperidol Hyoscine Butylbromide Hyoscine Hydrobromide Levemepromazine Lorazepam Metoclopramide Olanzapine Ondansetron Prochlorperazine Other

12. Thank you very much for completing this survey. The results will be presented at the January audit meeting. Please feel free to make any comments.